FDA has been updating its eMDR System Enhancements page to give industry early notice of upcoming electronic Medical Device Reporting changes. These updates are especially important for high-volume submitters and companies using third-party applications to create eMDR submission files. FDA notes that these firms should use the information to plan system updates and align with eMDR enhancements as soon as possible.

For medical device and combination product manufacturers, this is more than a technical update. It is a reminder that postmarket reporting is only as strong as the systems, workflows, and data controls behind it.

What FDA is changing

FDA’s current eMDR enhancement schedule includes several important updates. FDA is consolidating eMDR with the Adverse Event Monitoring System (AEMS). The electronic MDR submission format and destination address are not expected to change, but FDA says there will be minor changes to certain acknowledgement error messages. FDA is also encouraging submitters to verify that their systems comply with the applicable XML specifications.

FDA also announced a scheduled outage from July 22, 2026 through July 27, 2026 for this deployment. Submissions sent during the maintenance window are expected to receive Ack1 and Ack2 as usual, but Ack3 and Ack4 will be delayed until after deployment is complete. FDA states that the Ack1 timestamp is considered the MDR receive date for regulatory purposes, so successful submissions during the maintenance window will not be considered late because of Ack3/Ack4 delays. FDA also instructs submitters affected by the downtime to include a specific maintenance-impact statement in Block H11 of Form FDA 3500A or the equivalent field.

Other updates include the transition away from non-compliant ISO 3166-1 alpha-2 country codes for AS2/API submitters, with FDA instructing firms to use GENC three-letter country codes instead, as well as updates to adverse event codes in Form 3500A sections F10 and H6 to align with IMDRF maintenance updates.

Why this matters for Quality

MDR reporting is often treated as a regulatory reporting task. But in practice, it depends on a much broader quality system.

A successful eMDR submission requires accurate complaint intake, proper event evaluation, correct coding, complete device information, timely decision-making, validated systems, and reliable transmission controls. If any part of that chain fails, the result can be late reporting, rejected submissions, incomplete event data, or weak postmarket signal detection.

That means eMDR readiness should involve more than Regulatory Affairs or IT. Quality, Complaint Handling, Postmarket Surveillance, Regulatory, IT, and any third-party system vendors should all be aligned.

What teams should do now

1) Review your eMDR submission workflow

Map the process from complaint intake through MDR evaluation, coding, approval, submission, acknowledgements, and follow-up. Make sure ownership is clear at each step.

2) Confirm system and vendor readiness

If you use AS2/API tools or third-party software, confirm whether updates are needed for the AEMS consolidation, acknowledgement handling, XML specification compliance, country-code formatting, and IMDRF code updates.

3) Update procedures and work instructions

Your SOPs should reflect how your team handles submission errors, delayed acknowledgements, system downtime, coding updates, resubmissions, and maintenance-window documentation.

4) Validate or revalidate changes as appropriate

System changes that affect MDR creation, coding, transmission, acknowledgement handling, or record retention should be assessed under change control and validated or verified based on risk.

5) Train the people doing the work

Complaint and MDR teams need to understand not only what changed, but how those changes affect day-to-day decisions, coding, timelines, and documentation.

A practical eMDR readiness checklist

Before the next deployment or coding update, ask:

• Are complaint and MDR workflows fully mapped?
• Are submission roles and approval responsibilities clear?
• Has your team assessed whether software or vendor updates are needed?
• Are country codes and adverse event codes aligned with FDA expectations?
• Do procedures explain how to manage delayed acknowledgements or system maintenance windows?
• Are changes captured through change control?
• Has testing been completed in the appropriate environment?
• Are training records updated?
• Can your team show evidence that the process remains compliant and under control?

Bottom line

FDA’s eMDR system enhancements may look technical, but the quality implications are practical. Postmarket reporting depends on more than submitting a file. It depends on controlled workflows, accurate data, validated systems, trained reviewers, and clear documentation.

For device and combination product manufacturers, now is the time to treat eMDR readiness as a quality system activity, not just an IT update.

If your organization needs support reviewing MDR workflows, validating system changes, strengthening complaint handling, or preparing postmarket documentation for inspection, QSN can help pressure-test the process before reporting issues become compliance risks.